Keynote Address

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

• M A Hussein
• F D Vrionis
• B G M Durie

Transfusions after nonmyeloablative or reduced-intensity conditioning regimens

• F Baron
• G Vanstraelen
• Y Beguin

Chronic graft-versus-host disease: where is promise for the future?

• D J Weisdorf

Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?

• J M Rowe

Five decades of therapy for multiple myeloma: a paradigm for therapeutic models

• R A Kyle

Clinical and biological features of favorable-risk acute myelogenous leukemia – is favorable-risk AML really favorable?

• G J Schiller

Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation

• M Mohty
• C Faucher
• D Blaise

Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation

• F R Appelbaum

Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia

• M Pallis
• N Russell

The role of allogeneic transplantation in high-risk acute myelogenous leukemia

• W R Drobyski

Unsolved issues in CLL biology and management

• G Dighiero

Diffuse alveolar hemorrhage: an evolving problem?

• D J Weisdorf

Prevention and therapy of fungal infections in bone marrow transplantation

• L R Baden

Donor leukocyte infusions in acute myelogenous leukemia

• D L Porter

Stem cells and diversity

• E A McCulloch

Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?

• S Heimfeld

New targets for therapy in acute myeloid leukemia

• F R Appelbaum

Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?

• R A Larson

Induction and postremission therapy: new agents

• R M Stone

Immunologic manipulation in AML: from bench to bedside

• MA Cooper
• MA Caligiuri